Skip 
Navigation Link
Medical Disorders
Resources
Basic InformationLookupsLatest News
Cost-Effectiveness of PCSK9 Inhibitors Called Into QuestionDemand for Liver Transplant for NASH Set to Continue RisingEarly Rotator Cuff Surgery Helps Return to ActivitySteroid Pills Usually Ineffective Against Bronchitis, Study Finds'Exoskeletons' May Help Kids With Cerebral Palsy WalkNew Cholesterol Drugs Vastly Overpriced, Study ContendsA Shot of Caffeine May Speed Wake-Up After AnesthesiaZika Hijacks Pregnant Woman's Immune SystemHernia Patients May Need Fewer Opioids After Surgery, Study FindsHealth Tip: Prevent DehydrationTravel Tips for Contact Lens WearersHigher Odds of Infection With Reduced Kidney FunctionMost Ulcerative Colitis Patients Do Not Achieve Target RemissionOral Contraceptive Use Linked to Lower Rheumatoid Arthritis RiskKidney Disease May Boost Odds of InfectionZika May Not Last in Semen as Long as ThoughtVirtual House Calls for Speedy, Effective Parkinson's CareNearly 4 Million Worldwide Die Each Year From Asthma, COPDPowerful New Cholesterol Med Won't Harm Memory, Easing ConcernsDiverse Spectrum of Neurologic Syndromes Seen With ZikaExposure to Particulate Matter Linked to Metabolic AlterationsAir Purifiers May Help the Smog-Stressed Heart'Fat But Fit' a Myth?Statin Use Among Nursing Home Residents Varies SignificantlyZika Virus Tied to Neurological Woes in AdultsAn Expert's Guide to Preventing Food PoisoningHeart Risk Up if Hospitalized for Pneumonia or SepsisSinging May Be Good Medicine for Parkinson's PatientsCPAP Doesn't Alter Renal Function in Coexisting OSA, CVDWhen Stress Hormone Falters, Your Health May SufferKidney Disease May Boost Risk of Abnormal HeartbeatCertain Jobs Linked to Raised Risk of Rheumatoid ArthritisMidlife Vascular Risk Factors Tied to Increased Risk of DementiaHigher Risk of CVD Persists After Hospital Stay for Severe InfectionAntibiotic Doesn't Prevent Lung Complication After Stem Cell TransplantHealth Tip: One of Three Adults Gets ShinglesBlood Pressure Fluctuations Tied to Dementia Risk in StudyDecline in Kids' Ear Infections Linked to Pneumococcal VaccineFDA Approves Mavyret for Hepatitis CDoes Less Sleep Make You Less Healthy?Diabetes Drug Shows Promise Against Parkinson'sReview Suggests Benefits of Aerobic Exercise in FibromyalgiaNovel Procedure Improves Kidney Transplant SuccessABP 501, Adalimumab Biosimilar, Safe and Effective, for PsoriasisSimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesScientists Gain Insight Into AllergiesHealth Tip: Cooling a Heat RashKnow the Signs of ConcussionDo Your Pearly Whites Sometimes Cause You Pain?Rates of Inflammatory Bowel Disease Down in Rural Areas
Questions and AnswersLinksBook Reviews
Related Topics

New Drugs Show Promise as First to Prevent Migraine

HealthDay News
by By Steven Reinberg
HealthDay Reporter
Updated: Jun 9th 2017

new article illustration

FRIDAY, June 9, 2017 (HealthDay News) -- A host of new drugs that appear to prevent migraine headaches are in the final stages of testing and approval in the United States.

"What's really exciting about this is that until this development, we have not had a migraine-specific preventive at all," said Dr. Peter Goadsby, a professor of neurology at the University of California, San Francisco.

These are the first drugs to prevent migraine made specifically for migraine patients, said Goadsby. He led a research trial, with findings scheduled for presentation Saturday at an American Headache Society meeting, in Boston.

The new injectable drugs work by blocking a migraine-related protein called the calcitonin gene-related peptide (CGRP) or the receptor it acts on.

"CGRP is a small molecule that's released from pain nerves in the head, and is a key part of the process of migraine," said Goadsby.

Migraine is a disabling disease affecting more than 36 million men, women and children in the United States. Besides headache, symptoms can include nausea, sensitivity to light and/or smells, mood changes, difficulty concentrating and visual disturbances.

Chronic migraine means headaches occur 15 or more days a month; episodic migraine occurs less frequently.

Most migraine-preventive drugs in use today have been repurposed from their original use, Goadsby said. These include antidepressants, or drugs to lower blood pressure or prevent seizures, he said.

They all have side effects, and patients usually pick one based on the side effects they can tolerate, not on the basis of how well it prevents migraine, Goadsby said.

His research -- funded by drug maker Amgen -- involved the new drug erenumab. In the phase 3 trial assessing the drug's effectiveness, nearly 1,000 patients with episodic migraine were randomly assigned to one of two doses of erenumab or placebo for six months.

Half the patients receiving monthly injections of the higher dose of erenumab experienced a 50 percent reduction in the number of migraines they suffered, Goadsby said. As a result, their quality of life improved, too.

Goadsby said the drug was well-tolerated. The only side effect was irritation at the site of the injection, which he said quickly went away.

In separate phase 2 trials testing erenumab's safety for chronic migraine sufferers, the drug was also tied to fewer attacks.

Goadsby hopes erenumab will be approved by the U.S. Food and Drug Administration and made available by mid-2018.

These and other trial results are making news at the American Headache Society meeting.

"It's very exciting, It's been a long time in coming," said Dr. Noah Rosen, director of Northwell Health's Headache Center in Great Neck, N.Y.

Anybody who deals with headache patients spends a lot of time explaining why heart medication, antidepressants and anti-seizure drugs are used to prevent migraine instead of headache medications, he said.

"This is a revolution," Rosen said. "What triptan medications like Imitrex did for the acute treatment of migraine, this will do for the prevention of migraine."

While erenumab works by blocking the receptor CGRP acts on, other drugs work by blocking CGRP itself. They include fremanezumab by Teva; eptinezumab from Alder Biopharmaceuticals, and galcanezumab from Eli Lilly and Co.

For these three medications, researchers reported results of phase 2 trials that tested the drugs' safety.

In each case, patients reported more headache-free days. And side effects, such as changes in blood pressure or potential liver damage, were found not to be a problem, researchers said.

In addition, the drugs started working the first week of treatment. In some cases, patients were also able to cut back their other medications, researchers found.

These drugs will need to go through larger phase 3 trials to evaluate their effectiveness before they can be considered for FDA approval.

Goadsby said the overall outlook is promising for migraine sufferers.

"There is light on the horizon, which is entirely new and specifically designed for them," he said. "So for the person who is completely frustrated . . . it's really going to change."

Data and conclusions presented at meetings are usually considered preliminary until published in a peer-reviewed medical journal.

More information

For more on migraine, visit the American Migraine Foundation.